News Releases

SEATTLE --(BUSINESS WIRE)--Apr. 24, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced today the appointment of Chris Peetz to its Board of Directors. Mr. Peetz, an experienced life sciences executive, currently serves as the Chief Executive Officer of Flashlight Therapeutics.

-- ALPN-202 is a potential novel immuno-oncology therapy providing dual PD-L1/CTLA-4 antagonism with CD28 costimulation -- -- Unique mechanism seeks to address lack of costimulatory activity of existing immuno-oncology therapies -- -- Data Presented at 2018 American Association for Cancer Research

New preclinical data on ALPN-202 program to be presented at 2018 American Association for Cancer Research Annual Meeting SEATTLE --(BUSINESS WIRE)--Mar. 28, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies

SEATTLE --(BUSINESS WIRE)--Mar. 14, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the 2018 American Association for Cancer

SEATTLE --(BUSINESS WIRE)--Feb. 27, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced the company will present at the Cowen 38 th Annual Health Care Conference in

-- Data Presented at 59 th American Society of Hematology Annual Meeting & Exposition -- SEATTLE --(BUSINESS WIRE)--Dec. 9, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today

-- Data Presented at 2017 San Antonio Breast Cancer Symposium -- SEATTLE --(BUSINESS WIRE)--Dec. 6, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced results of a

New preclinical data to be presented at multiple upcoming scientific meetings Strong balance sheet with $87.2 million in cash, cash equivalents, and short-term investments SEATTLE --(BUSINESS WIRE)--Nov. 13, 2017-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading immunotherapy company focused

-- Company’s vIgD Platform Well Positioned to Realize Next Generation Immuno-Oncology Therapeutics -- SEATTLE --(BUSINESS WIRE)--Nov. 10, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and